CGTX Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Cognition Therapeutics Inc (CGTX) following the 2026 Q2 hedge fund 13F filings?

As of today, CGTX has moved -1.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -5.7%. Since the quarter end (June 30, 2026), CGTX gained -13.4% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Cognition Therapeutics Inc (CGTX)

65 + Investors. Track Smart Money conviction in CGTX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CGTX

Based on 65 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds reduced or closed their CGTX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

📊

High ownership — 83% of 3.0Y peak

83% of all-time peak

65 funds currently hold this stock — 83% of the 3.0-year high of 78 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.

🚀

Fast accumulation — +35% more funds vs a year ago

fund count last 6Q

+17 new funds entered over the past year (+35% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 54% buying

27 buying23 selling

Last quarter: 27 funds bought or added vs 23 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-8 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 31 → 17 → 12 → 4. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

📌

Mixed — 32% long-term, 20% new

■ 32% conviction (2yr+) ■ 48% medium ■ 20% new

Of the 65 current holders: 21 (32%) held >2 years, 31 held 1–2 years, and 13 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💰

Value +60% but shares only +5% — price-driven

Value

+59%

+5%

Last quarter: the total dollar value of institutional holdings rose +60%, but actual share count only changed +5%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

⚠️

Saturation — most institutions already know this story

8 → 31 → 17 → 12 → 4 new funds/Q

New funds entering each quarter: 31 → 17 → 12 → 4. Far fewer institutions are entering now vs. a year ago. When the pool of potential new buyers shrinks this fast, future price support from institutional inflows weakens significantly.

📊

Mixed cohorts — 38% veterans, 45% new entrants

■ 38% veterans ■ 17% 1-2yr ■ 45% new

Of 65 current holders: 25 (38%) held 2+ years, 11 held 1–2 years, 29 (45%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

📋

Smaller funds dominant — 14% AUM from top-100

14% from top-100 AUM funds

14 of 65 holders rank in the top 100 by AUM, but together hold only 14% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

2.8

out of 10

Low Exit Risk

Exit risk score 2.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	65	74	-12.16%
13F Shares	23M	21M	5.48%
Total Value	$26M	$16M	59.54%
New Positions	4	12	-8
Increased Positions	23	18	+5
Closed Positions	13	16	-3
Reduced Positions	10	14	-4
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

-12.16%

13F Shares

23M

21M

5.48%

Total Value

$26M

$16M

59.54%

New Positions

-8

Increased Positions

Closed Positions

-3

Reduced Positions

-4

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

65 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CGTX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CGTX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	BIOS Capital Management, LP	16.56%	6,000,000	$6.9M
2	Dauntless Investment Group, LLC	0.34%	371,701	$427K
3	CM Management, LLC	0.33%	450,000	$518K
4	Chescapmanager LLC	0.10%	997,029	$1.1M
5	American Financial Group Inc	0.08%	205,000	$236K
6	Hilton Capital Management, LLC	0.04%	548,950	$631K
7	DAVENPORT & Co LLC	0.02%	4,259,511	$4.9M
8	Fca Corp /Tx	0.01%	52,536	$60K
9	Sigma Planning Corp	0.01%	362,265	$417K
10	Voss Capital, LP	0.01%	175,000	$201K
11	Texas Capital Bank Wealth Management Services Inc	0.01%	143,296	$165K
12	Tocqueville Asset Management L.P.	0.00%	320,500	$369K
13	Bangor Savings Bank	0.00%	40,519	$47K
14	McAdam, LLC	0.00%	64,553	$74K
15	Barry Investment Advisors, LLC	0.00%	10,000	$12K
16	Essex Financial Services, Inc.	0.00%	40,000	$46K
17	Bryn Mawr Trust Advisors, LLC	0.00%	29,050	$33K
18	XTX Topco Ltd	0.00%	78,471	$90K
19	Renaissance Technologies LLC	0.00%	693,288	$797K
20	CWA Asset Management Group, LLC	0.00%	23,000	$26K
21	Empirical Financial Services, LLC d.b.a. Empirical Wealth Management	0.00%	48,000	$55K
22	Private Management Group Inc	0.00%	24,000	$28K
23	Circle Wealth Management, LLC	0.00%	48,842	$56K
24	Versant Capital Management, Inc	0.00%	3,257	$4K
25	Retirement Planning Group, LLC	0.00%	10,000	$12K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Cognition Therapeutics Inc (CGTX)

What does the Smart Money Trend signal show for CGTX?

Selling streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds reduced or closed their CGTX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CGTX?

Slight buying edge — 54% buying: Last quarter: 27 funds bought or added vs 23 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CGTX holders?

Smaller funds dominant — 14% AUM from top-100: 14 of 65 holders rank in the top 100 by AUM, but together hold only 14% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held CGTX?

Mixed — 32% long-term, 20% new: Of the 65 current holders: 21 (32%) held >2 years, 31 held 1–2 years, and 13 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Cognition Therapeutics Inc (CGTX) following the 2026 Q2 hedge fund 13F filings?

As of today, CGTX has moved -1.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -5.7%. Since the quarter end (June 30, 2026), CGTX has gained -13.4% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Cognition Therapeutics Inc (CGTX)

Smart Money Signals — CGTX

Selling streak — 2 quarters in a row

High ownership — 83% of 3.0Y peak

Fast accumulation — +35% more funds vs a year ago

Slight buying edge — 54% buying

Fewer new buyers each quarter (-8 vs last Q)

Mixed — 32% long-term, 20% new

Value +60% but shares only +5% — price-driven

Saturation — most institutions already know this story

Mixed cohorts — 38% veterans, 45% new entrants

Smaller funds dominant — 14% AUM from top-100

Institutional Sentiment Summary — CGTX

Hedge Fund Ownership: CGTX

Market Analysis: CGTX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CGTX

Is It Too Late to Buy Cognition Therapeutics Inc (CGTX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: CGTX

Statistics: CGTX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Cognition Therapeutics Inc (CGTX)

Welcome to 13Foresight!